J&J’s Growth Plan Calls For Mega-Blockbusters And A Leading Oncology Franchise
Johnson & Johnson laid out long-term revenue growth guidance and plans for its Innovative Medicines pipeline during an R&D day.
You may also be interested in...
CEO Joaquin Duato said J&J is agnostic on size when it comes to business development but has generally found more value creation in earlier-stage deals.
CEO Joaquin Duato told the J.P. Morgan Healthcare Conference that the drug maker hopes the $2bn acquisition can make one of its lead candidates, ARX517, the first PSMA-directed ADC for prostate cancer.
Johnson & Johnson’s historical strength in immunology will form the foundation of a renewed push in the field, with novel candidates for indications such as psoriasis, arthritis and inflammatory bowel disease.